Showing results (171-180 of 361) with videos related to
Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modelingChi Tarn, Erin Merkel, Adrian A Canutescu, et al.Breast Cancer Research : BCR|February 10, 2012
Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinomaGinette Serrero, Douglas M Hawkins, Binbin Yue, et al.Cancer Science|April 24, 2003
Expression of constitutively activated EGFRvIII in non-small cell lung cancerIsamu Okamoto, Lawrence C Kenyon, David R Emlet, et al.Cell Death & Disease|May 25, 2024
Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancerDavid Standing, Prasad Dandawate, Sumedha Gunewardena, et al.Gynecologic Oncology|August 14, 2012
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancerKimberly K Leslie, Michael W Sill, Heather A Lankes, et al.Journal of Extracellular Vesicles|February 18, 2021
WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1Meizhang Li, Rupal Soder, Sunil Abhyankar, et al.Cancer Research|June 4, 2009
Biological significance of prolactin in gynecologic cancersVera V Levina, Brian Nolen, YunYun Su, et al.BMC Cancer|June 29, 2005
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcomeMaría I Nunez, Daniel G Rosen, John H Ludes-Meyers, et al.Gynecologic Oncology|November 1, 2011
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group studyAgustin A Garcia, Michael W Sill, Heather A Lankes, et al.Stem Cell Reviews and Reports|August 3, 2020
A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host DiseaseRupal P Soder, Buddhadeb Dawn, Mark L Weiss, et al.Pageof 37